Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioGenesis tries again

This article was originally published in The Gray Sheet

Executive Summary

March meeting will provide another opportunity for firm to present case for PMA approval of PMR percutaneous myocardial revascularization system. FDA deemed the supplemental application "not approvable" in December 2002 (1"The Gray Sheet" March 3, 2003, p. 3). If a "favorable outcome" cannot be reached, CardioGenesis could opt to go before FDA's Medical Devices Dispute Resolution Panel...
Advertisement

Related Content

CardioGenesis’ PMR On Deck For FDA Dispute Resolution Panel Review
CardioGenesis’ PMR On Deck For FDA Dispute Resolution Panel Review
Advertisement
UsernamePublicRestriction

Register

MT019697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel